Valuation : AstraZeneca PLC

Market Cap 25TCr 22TCr 20TCr 19TCr 35TCr 23,71000Cr 35TCr 2,41500Cr 94TCr 12,12200Cr 94TCr 92TCr 39,82000Cr P/E 2026 *
20.8x
P/E 2027 * 18.2x
Enterprise Value 27TCr 23TCr 22TCr 20TCr 37TCr 25,53500Cr 38TCr 2,60100Cr 1,00900Cr 13,05500Cr 1,01500Cr 99TCr 42,88700Cr EV / Sales 2026 *
4.27x
EV / Sales 2027 * 3.93x
Free-Float
96.63%
Yield 2026 *
2.06%
Yield 2027 * 2.2%
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
-8.57%-.--% - - 25TCr
+0.39%-2.15%+58.30%+108.49% 1,03400Cr
+1.53%+1.64%+54.11%+70.78% 65TCr
+0.45%-0.85%+23.00%+78.41% 46TCr
+0.49%-5.19%+33.28%+35.53% 34TCr
+0.27%+3.26%+29.76%+47.50% 31TCr
+0.12%-2.11%+0.60%+12.03% 25TCr
+0.77%-0.03%+53.42%+73.30% 24TCr
+2.64%-1.08%-15.85%-53.97% 20TCr
-0.22%+0.88%+32.55%+98.78% 19TCr
Average -0.21%-2.88%+29.91%+52.32% 40.8TCr
Weighted average by Cap. +0.10%-3.31%+38.78%+67.84%

Financials

2026 *2027 *
Net sales 6.32TCr 5.46TCr 5.14TCr 4.68TCr 8.75TCr 5,97400Cr 8.82TCr 61TCr 24TCr 3,05400Cr 24TCr 23TCr 10,03300Cr 6.68TCr 5.76TCr 5.43TCr 4.95TCr 9.25TCr 6,31200Cr 9.32TCr 64TCr 25TCr 3,22700Cr 25TCr 25TCr 10,60100Cr
Net income 1.2TCr 1.04TCr 977.02Cr 890.18Cr 1.66TCr 1,13600Cr 1.68TCr 12TCr 4.49TCr 58TCr 4.51TCr 4.42TCr 1,90700Cr 1.36TCr 1.17TCr 1.11TCr 1.01TCr 1.88TCr 1,28600Cr 1.9TCr 13TCr 5.08TCr 66TCr 5.11TCr 5TCr 2,15900Cr
Net Debt 1.93TCr 1.67TCr 1.57TCr 1.43TCr 2.67TCr 1,82600Cr 2.69TCr 19TCr 7.22TCr 93TCr 7.26TCr 7.1TCr 3,06600Cr 1.17TCr 1.01TCr 946.94Cr 862.78Cr 1.61TCr 1,10100Cr 1.62TCr 11TCr 4.35TCr 56TCr 4.38TCr 4.28TCr 1,84900Cr
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
161.82USD
Average target price
212.68USD
Spread / Average Target
+31.43%

Quarterly revenue - Rate of surprise